TAT and Alzheimer disease: Monosialotetrahexosylganglioside (GM1), a lipid with high binding affinity to Aβ, could achieve excellent targeted effects on the AD brain.[17] The transcriptional activator protein (TAT) is one of the most widely studied transmembrane peptides in the brain delivery system.[22, 23] Thus, TAT modification could enhance the brain accumulation of nanoparticles.